NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen

Program leverages NeoGenomics' expertise to provide ovarian cancer patients critical insights to ensure they are getting the right treatment FT. MYERS, FL / ACCESSWIRE / November 18, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers (EOC).Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq:IMGN), EOC patients will have access to the FOLR1 IHC CDx test (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to measure the expression of a protein called folate receptor alpha (FRα).

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

The cancer screening company showed its turnaround may be working.

Why Shares of NeoGenomics Jumped 53.9% This Week

Neo Performance Materials Inc. (OTCPK:NOPMF) Q3 2022 Earnings Conference Call November 11, 2022 10:00 AM ET Company Participants Ali Mahdavi – Head-Investor Relations Constantine Karayannopoulos – President and Chief Executive Officer Rahim Suleman – Chief Financial Officer Conference Call Participants David Ocampo – Cormark Securities Mark Neville – Scotiabank Ian Gillies – Stifel Operator Please stand by, we're about to begin. Good day and welcome to the Neo Performance Materials Third Quarter 2022 Earnings Call.

Neo Performance Materials Inc. (NOPMF) Q3 2022 Earnings Call Transcript

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - BTIG Mason Carrico - Stephens Tejas Savant - Morgan Stanley Dan Brennan - Cowen Mike Matson - Needham & Company Operator Good day, ladies and gentlemen, and welcome to the NeoGenomics Third Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.

NeoGenomics, Inc. (NEO) Q3 2022 Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for

FORT MYERS, FL / ACCESSWIRE / October 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, is providing an update on its discussions with MolDX and on its commercial launch activities for RaDaRTM , its proprietary assay for the detection of minimal residual disease (MRD) and recurrence. Late last week, MolDX informed the Company that additional clinical evidence is needed in order to secure Medicare coverage for RaDaRTM for Colorectal Cancer (CRC).

NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

AppLovin Corp

Enovix Corporation

1Life Healthcare

Prometheus Biosciences

Signify Health

Sotera Health

Scotts Miracle-Gro

Verve Therapeutics

WeWork

Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap companies.

These Were The Five Best And Worst Performing Mid-Cap Stocks In Q3 2022

FT. MYERS, FL / ACCESSWIRE / October 13, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its third quarter 2022, financial results on Tuesday, November 8, 2022. The Company has scheduled a webcast and conference call to discuss their third quarter 2022 results on Tuesday, November 8, 2022 at 8:30 AM EDT.

NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022

NeoGenomics continues to present with heightened downside risk and doesn't warrant inclusion into equity portfolios. NEO shares have been heavily compressed in 2022 as investors unload names with weakening fundamentals.

NeoGenomics: Market Punishment Continues, But Looks Justified

Inivata and Collaborators to Present New Data to Support the Application of RaDaR ™ MRD Assay Across Tumor Types at ESMO Congress 2022

Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022

Data Supports the Application of RaDaR™ MRD Assay Across Tumor Types Early Research on Potential Biomarker in Melanoma Patients Unresponsive to Immunotherapy FT. MYERS, FL / ACCESSWIRE / September 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announces that its liquid biopsy focused subsidiary Inivata Limited ("Inivata"), alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place September 9th-13th, 2022.

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2022 Earnings Conference Call August 12, 2022 10:00 AM ET Company Participants Ali Mahdavi - Senior Vice President of Corporate Development and Capital Markets Constantine Karayannopoulos - President and Chief Executive Officer Rahim Suleman - Executive Vice President and Chief Financial Officer Conference Call Participants Yuri Lynk - Canaccord Genuity Corp. Frederic Bastien - Raymond James Ltd. Mark Neville - Scotiabank David Ocampo - Cormark Securities Ltd.

Neo Performance Materials Inc. (NOPMF) CEO Constantine Karayannopoulos on Q2 2022 Results - Earnings Call Transcript

NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault – Interim CEO Charlie Eidson – Director of Investor Relations Bill Bonello – Chief Financial Officer Chris Smith – Incoming Chief Executive Officer David Sholehvar – President, Clinical Division Vishal Sikri – President, Pharma Services Division and President-Inivata Conference Call Participants Brian Weinstein – William Blair Alex Nowak – Craig-Hallum David Westenberg – Piper Sandler Puneet Souda – SVB Securities Dan Brennan – Cowen Andrew Cooper – Raymond James Mark Massaro – BTIG Derik de Bruin – Bank of America Yuko Oku – Morgan Stanley David Delahunt – Goldman Sachs Mike Matson – Needham Mason Carrico – Stephens, Inc. Operator Good day, ladies and gentlemen, and welcome to the NeoGenomics Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.

NeoGenomics, Inc.'s (NEO) CEO Lynn Tetrault on Q2 2022 Results - Earnings Call Transcript

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates

Second-Quarter 2022 Results and Highlights Consolidated revenue increased 3% to $125 million Clinical Services revenue increased 4% to $106 million Pharma Services revenue decreased 4% to $19 million Chris Smith appointed CEO effective August 15, 2022 FORT MYERS, FL / ACCESSWIRE / August 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its second-quarter results for the period ended June 30, 2022. "During a challenging time in our business, our people have rallied together as we welcome talented new leaders, embark on an enterprise wide performance improvement plan, and continue to move RaDaR forward.

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board FT. MYERS, FL / ACCESSWIRE / July 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that industry veteran Chris Smith has been appointed Chief Executive Officer and a member of the board of directors effective August 15, 2022.

NeoGenomics Announces Chief Executive Officer Appointment

FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2022, financial results on Tuesday, August 9, 2022. The Company has scheduled a webcast and conference call to discuss their second quarter 2022 results on Tuesday, August 9, 2022 at 8:30 AM EDT.

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your NeoGenomics investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit yo

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) investors concerning the Company's possible violations of federal securities laws. On March 28, 2022, after the market closed, NeoGenomics announced that its Chief Executive Officer, Mark Mallon, had resigned, less than a year after accepting the position. The Company also stated that revenue for first quarter 2022 would be “bel

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 28, 2022, after the market closed, NeoGenomics announced that its Chief Executive Officer, Mark Mallon, had resigned, less than a year after accepting the positio

The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

Inivata and Collaborators Announce New D ata Demonstrating Clinical Potential of its RaDa R™ MRD Test in HR + HER2- Breast Cancer

Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast Cancer

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has announced new data in support of its RaDaRTM assay for the detection of minimal residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The data, from the CHiRP study (Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer), has been published in the Journal of Clinical Oncology and was presented in part at the 2022 ASCO® Annual Meeting which took place 3-7 June 2022 in Chicago, IL.

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

OAKLAND, Calif.--(BUSINESS WIRE)---- $NEO #NEO--Gibbs Law Group is investigating potential legal claims on behalf of NEO investors.

News for NeoGenomics Stock (NEO)